Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial

The Lancet

Volumn 379, Issue 9835, 2012, Pages 2429-2438

  DeJesus, Edwin ^a   Rockstroh, Jürgen K ^b   Henry, Keith ^c   Molina, Jean Michel ^d   Gathe, Joseph ^e   Ramanathan, Srinivasan ^f   Wei, Xuelian ^f   Yale, Kitty ^f   Szwarcberg, Javier ^f   White, Kirsten ^f   Cheng, Andrew K ^f   Kearney, Brian P ^f  

^a ORLANDO IMMUNOLOGY CENTER   (United States)

^b UNIVERSITY OF BONN   (Germany)

^c HENNEPIN COUNTY MEDICAL CENTER   (United States)

^d SAINT LOUIS HOSPITAL   (France)

^e Therapeutic Concepts   (United States)

^f GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; COBICISTAT; CREATININE; ELVITEGRAVIR; EMTRICITABINE; RITONAVIR; TENOFOVIR DISOPROXIL; TRIACYLGLYCEROL; VIRUS RNA;

ABDOMINAL DISCOMFORT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPIRATION PNEUMONIA; BURKITT LYMPHOMA; CERVICOBRACHIAL NEURALGIA; COMPARATIVE STUDY; COMPUTER; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DERMATITIS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG ERUPTION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; EYE DISEASE; EYE JAUNDICE; FATIGUE; FEVER; FLATULENCE; GLOMERULUS FILTRATION RATE; HEPATITIS C; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPESTHESIA; INTOXICATION; JAUNDICE; KIDNEY DISEASE; MEDIASTINUM DISEASE; MEDICAL STAFF; MUSCULOSKELETAL DISEASE; NAUSEA; NEOPLASM; NEPHROTOXICITY; PHASE 3 CLINICAL TRIAL; PLEURISY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHABDOMYOLYSIS; SCHIZOPHRENIA; SCREENING; SELF ESTEEM; SIDE EFFECT; SKIN DISEASE; TELEPHONE; TREATMENT OUTCOME; VASCULAR DISEASE; VOMITING;

EID: 84862843404     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60918-0     Document Type: Article

References (38)

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 2011; 1-166. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 22 Feb, 2012).
2. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adults with HIV infection; 2010 Recommendations of the International AIDS Society-USA Panel. JAMA 2010; 304: 321-33.
3. European AIDS Clinical Society (EACS) Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe. Version 6.0. London: British HIV Association, 2011; 1-61.
4. Gazzard BG on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008; 9: 563-608.
5. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 2010; 53: 323-32.
6. Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009; 50: 367-74.
7. Llibre JM, Arribas JR, Domingo P, et al. Spanish Group for FDAC Evaluation. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. AIDS 2011; 25: 1683-90.
8. Hodder SL, Mounzer K, DeJesus E, et al. Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF. AIDS Patient Care STDS 2010; 24: 87-96.
9. Airoldi M, Zaccarelli M, Bisi L, et al. One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects. Patient Prefer Adherence 2010; 4: 115-25.
10. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people. AIDS 2010; 24: 2835-40.
11. Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011; 25: F7-12.
12. US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements. 2002; http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070968.pdf (accessed April 24, 2012).
13. Smith F, Hammerstrom T, Soon G, et al. A meta-analysis to assess the FDA DAVP's TLOVR algorithm in HIV submissions. Drug Inf J 2011; 45: 291-300.
14. Gallant J, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60. (Pubitemid 43113030)
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70. (Pubitemid 29135798)
16. Ramanathan S, Shen G, Cheng A, Kearney BP. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137. J Acquir Immune Defic Syndr 2007; 45: 274-79. (Pubitemid 47012373)
17. German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancercontaining single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr 2010; 55: 323-29.
18. Sax PE, DeJesus E, Mills A, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379: 2439-48.
19. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006; 43: 1-5. (Pubitemid 44306480)
20. Molina JM, LaMarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study. Lancet Infect Dis 2012; 12: 27-35.
21. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378: 229-37.
22. Molina J-M, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378: 238-46.
23. Daar ES, Tierney C, Fischl M, et al. ACTG 5202: Final results of abacavir/lamivudine (ABC/3TC) or tenofovir DF/emtricitabine (TDF/FTC) with either efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in treatment-naive HIV-infected patients. 17th Conference on Retroviruses and Opportunistic Infections (CROI); San Francisco, CA, USA; 16-19 Feb, 2010 (abst 59LB).
24. Lennox JL, DeJesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374: 796-806.
25. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55: 39-48.
26. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with atazanavir plus fixed-dose emtricitabine/tenofovir DF in the initial treatment of HIV infection. AIDS 2011; 25: 1881-86.
27. Lepist EI, Murray BP, Tong L, et al. Effect of cobicistat and ritonavir on proximal renal tubular cell uptake and efflux transporters. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, IL, USA. 17-20 Sept, 2011. Abstract A1-1724.
28. German P, Lui C, Warren D, et al. Effect of cobicistat on glomerular filtration rate (GFR) in subjects with normal and impaired renal function. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Chicago, IL, USA; 17-20 Sept, 2011. Poster H2-804.
29. Tong L, Phan TK, Robinson KL. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007; 51: 3498-504. (Pubitemid 47519335)
30. VIREAD® (tenofovir disoproxil fumarate) tablets. US Prescribing Information. Gilead Sciences, Foster City, CA, USA. Revised October 2010.
31. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 2007; 8: 164-72. (Pubitemid 47121761)
32. Smith KY, Weinberg WG, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/ emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther 2008; 5: 5.
33. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther 2011; 16: 339-48.
34. Branson BM, Handsfield HH, Lampe MA, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings; Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 2006; 55: 1-17.
35. Cohen C, Davis KL, Meyers J. Association between daily antiretroviral pill burden and hospitalization risk in a medicaid population with HIV. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Chicago, IL, USA; 17-20 Sept, 2011. Poster H2-791.
36. Sax PE, Meyers J, Mugavero M, Davis KL. Adherence to antiretroviral treatment regimens and correlation with risk of hospitalization among commercially insured HIV patients in the United States. 10th International Congress on Drug Therapy in HIV Infection; Glasgow, UK; 7-11 Nov, 2010. Poster O113.
37. Stone VE, Jordan J, Tolson J, Pilon T. Potential impact of once daily regimens on adherence to HAART. 40th Annual Meeting of the Infectious Disease Society of America; Chicago, IL, USA; 24-27 Oct, 2002. Abstract 486.
38. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000; 30 (suppl 2): S171-76. (Pubitemid 32268984)